Media Articles Related to Stelara (Ustekinumab)
Brodalumab Beats Stelara in Psoriasis Trial, Sponsors Say
Source: MedPage Today Dermatology [2014.11.11]
(MedPage Today) -- More patients achieve total plaque clearance in topline results.
CHMP Backs Secukinumab, Apremilast for Psoriasis
Source: Medscape Medical News Headlines [2014.11.21]
The European Medicines Agency committee has recommended secukinumab and apremilast for moderate to severe plaque psoriasis and apremilast for active psoriatic arthritis.
Positive results from second pivotal Phase 3 study of Brodalumab in patients with moderate-to-severe plaque psoriasis announced
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.11.13]
Amgen and AstraZeneca has announced that AMAGINE-3(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis...
New research reveals true impact of psoriasis
Source: Dermatology News From Medical News Today [2014.11.03]
Innovative research published in the latest edition of the British Journal of Dermatology reveals the causes behind the emotional distress experienced by people with psoriasis.
Lesion-healing mechanism identified in psoriasis
Source: Dermatology News From Medical News Today [2014.10.29]
A UC Irvine-led study has revealed the underlying genetic factors that help repair skin lesions caused by psoriasis, which could engender new methods of controlling the lingering condition.Dr.
Published Studies Related to Stelara (Ustekinumab)
An update on the long-term safety experience of ustekinumab: results from the
psoriasis clinical development program with up to four years of follow-up. 
severe psoriasis treated for up to four years... CONCLUSION: The safety profile of long-term ustekinumab treatment with up to four
Long-term safety experience of ustekinumab in patients with moderate to severe
psoriasis (Part II of II): results from analyses of infections and malignancy
from pooled phase II and III clinical trials. 
exposed up to 3 years... CONCLUSIONS: The emerging safety profile of ustekinumab remains favorable and
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. 
This phase 2/3, double-blind, placebo-controlled study was designed to assess the
safety and efficacy of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis. Overall, 158 patients were randomized to receive
ustekinumab 45 or 90 mg at weeks 0, 4, and every 12 weeks, or placebo with
cross-over to ustekinumab at week 12...
Long-term safety experience of ustekinumab in patients with moderate-to-severe
psoriasis (Part I of II): results from analyses of general safety parameters from
pooled Phase 2 and 3 clinical trials. 
ustekinumab through 3 years of treatment... CONCLUSIONS: The safety profile of continued ustekinumab exposure through up to 3
Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]
Background Different biological agents are used for the treatment of psoriasis. Previous data have shown adalimumab to be the most efficient drug in terms of cost-efficacy... The robustness of this finding was confirmed by sensitivity analysis.
Clinical Trials Related to Stelara (Ustekinumab)
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis [Recruiting]
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of
ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis [Recruiting]
This study will provide data on sasety and efficacy of Ustekinumab in patients suffering
from Palmo-Plantar Pustular Psoriasis (PPPP) or Palmo-Plantar Pustulosis(PPP)
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) [Recruiting]
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients
with moderate to severe psoriasis.
TRANSIT - A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate [Recruiting]
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who
receive ustekinumab following an inadequate response to methotrexate therapy. The study
will provide information for doctors on how to manage the transfer from methotrexate to the
biologic agent ustekinumab. The study is designed to compare two methods of transferring
patients from methotrexate to ustekinumab. The two methods being compared are
discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation
of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients
with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.
Reports of Suspected Stelara (Ustekinumab) Side Effects
Myocardial Infarction (71),
Drug Ineffective (67),
OFF Label USE (41),
Drug Dose Omission (34),
Psoriatic Arthropathy (34), more >>